Cidara To Take Rezafungin Into Phase III In Two Severe Infection Indications

Two-week treatment data comparing the investigational echinocandin antifungal with caspofungin shows trend toward better cure rate with similar efficacy. Cidara plans Phase III trials for treatment and prevention of difficult-to-treat infections.

Infectious disease

More from R&D

More from Scrip